Avitene Microfibrillar Collagen Hemostat (MCH) Non-Woven Web Webber
C.R. Bard, Inc. · Decision date Sep 29, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-09-29 for PMA supplement P800002/S036, submitted by C.R. Bard, Inc. as a 30-Day Notice. The supplement covers a modification of manufacturing equipment for Avitene Microfibrillar Collagen Hemostat (MCH) Non-Woven Web production. The underlying device is an absorbable, collagen-based hemostatic agent (product code LMF) associated with general and plastic surgery.
The recorded reason is a process change affecting manufacturer, sterilizer, packager or supplier. The source does not identify which equipment changed, what the modification was, or which manufacturing site is involved, and it provides no documents. The decision therefore concerns the equipment change described in the notice, not a new approval of the Avitene MCH Non-Woven Web system as a whole. No clinical or performance conclusions follow from this record.
FDA approval order statement
modification of manufacturing equipment for Avitene MCH Non-Woven Web production
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 29, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P800002/S036
- Regulatory pathway
- PMA supplement
- Applicant
- C.R. Bard, Inc.
- Product code
- LMF
- Decision code
- OK30
- Decision date
- Sep 29, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, collagen based.
- Applicant
- C.R. Bard, Inc.
- Product code
- LMF
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P800002. Subsequent supplements may change the device or its indications.
FDA decision timeline
P800002 · Original PMA
AVITENE MICROFIBRILLAR COLLAGEN HEMOSTAT NON-WOVEN WEB
P800002/S036 received
Application receipt date recorded by FDA.
P800002/S036 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P800002. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P800002
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| C.R. Bard, Inc. | PMA approval | Oct 24, 1980 | FDA |
Explore the linked device profile
Other records with product code LMF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
| Integra LifeSciences Corporation | PMA supplement | Sep 18, 2026 | FDA | |
SURGIFOAM Absorbable Gelatin SpongeP990004/S080 | Ferrosan Meidcal Devices A/S | PMA supplement | Sep 18, 2026 | FDA |
| Ferrosan Meidcal Devices A/S | PMA approval | Sep 30, 1999 | FDA | |
| Integra LifeSciences Corporation | PMA approval | Nov 8, 1985 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
C.R. Bard, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 160 New Boston St., Woburn, MA, 01801
Sources and methodology
- Original FDA record: P800002/S036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
